TALAPRO-2
The PARP-plus-hormone combination that eventually showed an overall survival benefit, in 2024-25.
805 all-comers: rPFS HR 0.63; HRR-mutant cohort rPFS HR 0.45. Final OS (2025) HR 0.80 all-comers, 0.62 HRR-mutant. FDA approval (2023) limited to HRR-mutant disease.
- Median 21.9 months with Placebo + enzalutamide.
- Talazoparib + enzalutamide: Median not reached.
- "Not reached" means that, when the data were analysed, more than half of that group had not yet had the event, which is good news for that group.
- A median is a midpoint: half the people did better than this and half did worse.
- Put another way, the treated group had about 37 percent lower chance of the event at any given time (hazard ratio 0.63, likely range 0.51 to 0.78).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- Median 45.8 vs 37 months with Talazoparib + enzalutamide compared with Placebo + enzalutamide; about 8.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 20 percent lower chance of the event at any given time (hazard ratio 0.8, likely range 0.66 to 0.96).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: First-line mCRPC: enzalutamide + talazoparib vs enzalutamide + placebo (all-comers and HRR-mutant cohorts). People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
805 participants enrolled.
Median not reached
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Radiographic progression-free survival, all comersprimary | Talazoparib + enzalutamide | 402 | Median not reached | 0.63 (0.51–0.78) | <0.0001 | link |
| Placebo + enzalutamide | 403 | 21.9 months | ||||
| Overall survival, all comers (final) | Talazoparib + enzalutamide | — | 45.8 months | 0.8 (0.66–0.96) | 0.016 | link |
| Placebo + enzalutamide | — | 37 months |
Pages like this
not linked directly; found by shared links- InstitutionHuntsman Cancer Institute, University of Utah
Shares Neeraj Agarwal, Talazoparib, Enzalutamide, BRCA1 / BRCA2 (HRD).
- TrialARCHES
Shares Enzalutamide, Prostate cancer.
- PersonJennifer K. Litton
Shares Talazoparib, PARP, BRCA1 / BRCA2 (HRD).
- TrialPROfound
Shares PARP, BRCA1 / BRCA2 (HRD), Prostate cancer.
- TrialEMBARK
Shares Enzalutamide, Prostate cancer.
- TrialMEVPRO-1
Shares Enzalutamide, Prostate cancer.
- ProductIniparib
Shares Talazoparib, PARP.
- TrialPOLO
Shares PARP, BRCA1 / BRCA2 (HRD).